Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Gains from Sales and Divestitures (2016 - 2025)

Bio-Techne (TECH) has 10 years of Gains from Sales and Divestitures data on record, last reported at $134000.0 in Q2 2025.

  • For Q2 2025, Gains from Sales and Divestitures rose 346.67% year-over-year to $134000.0; the TTM value through Jun 2025 reached $134000.0, up 346.67%, while the annual FY2025 figure was $134000.0, 346.67% up from the prior year.
  • Gains from Sales and Divestitures reached $134000.0 in Q2 2025 per TECH's latest filing, up from $30000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $134000.0 in Q2 2025 and bottomed at $30000.0 in Q2 2024.
  • Average Gains from Sales and Divestitures over 5 years is $64600.0, with a median of $54000.0 recorded in 2022.
  • Peak YoY movement for Gains from Sales and Divestitures: decreased 25.93% in 2023, then surged 346.67% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $65000.0 in 2021, then decreased by 16.92% to $54000.0 in 2022, then fell by 25.93% to $40000.0 in 2023, then decreased by 25.0% to $30000.0 in 2024, then soared by 346.67% to $134000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $134000.0 in Q2 2025, $30000.0 in Q2 2024, and $40000.0 in Q2 2023.